A Case of Pulmonary Fibrosis and COVID-19-Related Pneumonia in a Pembrolizumab-Treated Patient

Pembrolizumab is used as a first-line treatment of non-small cell lung cancer. Pneumonitis and interstitial lung disease are among the most common immune-related adverse events. The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections on patients with cancer treated with...

Full description

Saved in:

Bibliographic Details
Main Authors:	Alberto Zolezzi, Gina Gualano, Annelisa Mastrobattista, Pietro Vittozzi, Virginia Di Bari, Carlotta Cerva, Silvia Mosti, Antonio Lugini, Fabrizio Albarello, Federica Di Stefano, Maria Beatrice Valli, Fabrizio Palmieri
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Series:	Infectious Disease Reports
Subjects:	pembrolizumab severe acute respiratory syndrome coronavirus 2 fibrotic-like pattern
Online Access:	https://www.mdpi.com/2036-7449/17/3/53
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

A Case of Pulmonary Fibrosis and COVID-19-Related Pneumonia in a Pembrolizumab-Treated Patient

Similar Items